Treatment of familial Mediterranean fever with anti-IL-1 beta antibodies

摘要

This disclosure relates to a novel use of IL-1²-ligand/IL-1 receptor disrupting compounds (herein referred to as "IL-1beta Compounds"); such as small molecular compounds disrupting IL-1² ligand-IL-1 receptor interaction, IL-1² antibodies or IL-1 receptor antibodies, e.g. IL-1² binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1² binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1² ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.